是时候定义和完善急性髓系白血病的维持治疗策略了。 - Suppr | 超能文献

Time to define and refine maintenance strategies in acute myeloid leukaemia.

作者信息

Chua Chong Chyn, Gómez-De León Andrés

机构信息

Monash Health, Monash University, Melbourne, VIC, Australia; Northern Hospital Epping, Melbourne, VIC, Australia; Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, VIC, Australia.

Haematology Service, Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Monterrey, 64460, Mexico; Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico; University Hospital Dr José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

出版信息

Lancet Haematol. 2024 Apr;11(4):e246-e247. doi: 10.1016/S2352-3026(24)00068-1.

DOI:10.1016/S2352-3026(24)00068-1

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Time to define and refine maintenance strategies in acute myeloid leukaemia.是时候定义和完善急性髓系白血病的维持治疗策略了。

Lancet Haematol. 2024 Apr;11(4):e246-e247. doi: 10.1016/S2352-3026(24)00068-1.

2

Is there a role for maintenance therapy in acute myeloid leukaemia?在急性髓系白血病中，维持治疗有作用吗？

Best Pract Res Clin Haematol. 2009 Dec;22(4):517-21. doi: 10.1016/j.beha.2009.09.001.

3

Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.阿扎胞苷和吉妥珠单抗奥唑米星用于高危急性髓性白血病的移植后维持治疗。

Br J Haematol. 2015 Jun;169(5):756-9. doi: 10.1111/bjh.13248. Epub 2014 Dec 17.

4

Chemotherapy of adult acute myeloid leukaemia.

Ann Acad Med Singap. 1990 Mar;19(2):175-7.

5

Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.利用自动化电子健康记录提取技术确定的儿科白血病课程中的实验室不良事件发生率：来自儿童肿瘤学组的回顾性队列研究。

Lancet Haematol. 2022 Sep;9(9):e678-e688. doi: 10.1016/S2352-3026(22)00168-5. Epub 2022 Jul 20.

6

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.索拉非尼联合标准疗法与安慰剂联合标准疗法治疗 60 岁及以下初诊急性髓系白血病患者（SORAML）：一项多中心、2 期、随机对照试验。

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

7

Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.诱导化疗后的部分缓解在急性髓系白血病中具有临床意义。

Br J Haematol. 2017 Apr;177(2):328-330. doi: 10.1111/bjh.14063. Epub 2016 Mar 31.

8

Acute myeloid leukaemia (AML).急性髓系白血病（AML）。

Biomed Pharmacother. 1987;41(4):196.

9

Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials.谁是急性髓系白血病（AML）的“老年”患者？两项英国国家癌症研究所（NCRI）/AML试验的调查。

Br J Haematol. 2014 Apr;165(1):147-51. doi: 10.1111/bjh.12705. Epub 2013 Dec 23.

10

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.60 岁或以上急性髓系白血病患者接受强化化疗后的完全缓解和早期死亡：一种用于预测结局的网络应用。

Lancet. 2010 Dec 11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3.

引用本文的文献

1

Patients with -Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.接受强化诱导治疗的携带 - 突变的急性髓系白血病患者因挽救治疗率较高而有更好的预后：一项单机构回顾性研究。

Cancers (Basel). 2024 Aug 7;16(16):2784. doi: 10.3390/cancers16162784.